All News
Anifrolumab, a type I IFN receptor antagonist, was effective in patients with SLE
to increase BICLA response versus placebo. Results of the TULIP-2 trial. #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
J Stone GCA pearls: Dry cough can be a symptom of occult GCA. Jaw claudication comes on quickly. Predicts +ve TAB.
Tongue ulcers in GCA occur on the lat. part of the mid tongue. This is a watershed area for blood supply.
Strawberry gums can be seen in GCA. #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
“TULIP-2 was a positive phase 3 trial in lupus, and there haven’t been many times before that those words have been spoken” - @EricFMorand
Anifrolumab in mod-severe SLE #ACR19 L17 @RheumNow @US_FDA https://t.co/8lqBmaWHW0
David Liew drdavidliew ( View Tweet)
Telitacicept is a recombinant fusion protein with the extracellular domain of TACI and the FC domain of human IgG1. #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Are urine metabolomics able to differentiate between healthy controls (HC), RA, SLE, & SpA? Small study of prevalent pts showed SLE and RA metabolomics v diff from controls and SpA. Don't know if diff early or pre clinical disease #ACR19 @RheumNow abstr 2127 https://t.co/mBh5nxRcqk
Janet Pope Janetbirdope ( View Tweet)
5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least one objective sign of inflammation or structural damage are more frequently associated with effectiveness #2776 by Molto #ACR19 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
What dose of MTX do you usually start with in a newly diagnosed rheumatoid arthritis patient? #ACR19 @RheumNow
Philip Robinson philipcrobinson ( View Tweet)
@_connectedcare @RheumNow @ACRheum My pearls (so far)
1. Use vitamin A to reduce SEs w MTX
2. Try doxycycline for refractory calcinosis in scleroderma
3. Use MTX with pegloticase to reduce infusion reactions
4. Anti-IL17 has activity in nr-axSpA
5. Patients think opiates are more effective than SNRIs or TCAs in FM
Philip Robinson philipcrobinson ( View Tweet)
@RheumNow #ACR19 #acrbest abs2470 ⬆️serum calprotectin in PsA pts associated w/presence of carotid plaque, ⬆️intima-media thickness & ⬆️CRP. potential novel bio marker of CV disease in PsA https://t.co/ech3Ll8Nka
Olga Petryna DrPetryna ( View Tweet)
As I leave #acr19, time to reflect. My goal is to uncover pearls that change what I do in my next few clinics. 3 this time. How many such pearls did you find? @RheumNow @ACRheum
Dr Irwin Lim _connectedcare ( View Tweet)
@rheumnow #ACR19 abs2854 internationPsART cohort data: age of onset defines if PSO or PSA starts first (PSO precedes in younger pts), Pustular PSO associated w/shorter time interval PSO to arthritis while nail involvement, plaque PSO & PSO family Hx associated w/ longer interval https://t.co/KtPXhYdbky
Olga Petryna DrPetryna ( View Tweet)
Do you still look at synovial fluid under the microscope? @rheumnow #acr19
k dao KDAO2011 ( View Tweet)
Baricitinib additional improvement in pain vs ADA despite accounting for effect on disease activity https://t.co/zAjS2dOayF @RheumNow
Dr. Arthur Lau ArthurRheum ( View Tweet)
Claims data showing switching from ETN or ADA to Tofa had higher drug survival vs cycling to another TNF. Does not provide reason for discontinuation though https://t.co/yTNHkKanJA @RheumNow #ACR19
Dr. Arthur Lau ArthurRheum ( View Tweet)
Weight loss in IgG4-RD NOT because of overwhelming systemic inflammation but from pancreatic involvement. Need pancreatic enzyme replacement. #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
Abstr#2729: 303 pts randomized. More pts achieved ASAS40 at Wk 16: IXE Q2W (40%), IXE Q4W (35%) vs PBO (19%, p< 0.01) and at Wk 52: IXE Q2W (31%), IXE Q4W (30%) vs PBO (13%, p< 0.01). Blocking IL-17A is a potential treatment option for patients with nr-axSpA. #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
Fantastic view of how specific defects in the immune system lead to various clinical presentations and laboratory abnormalities. Dr. Mahta Mortezavi #ACR19 @RheumNow https://t.co/ht7VBhDdpR
Jonathan Hausmann MD hausmannMD ( View Tweet)
Drs. Davila and Solow say “No good data to suggest that biologic DMARDs contribute to progression of MGUS so okay to treat as you normally would.” #ACR19 @RheumNow https://t.co/5r2W4q1t5c
Dr. Rachel Tate uptoTate ( View Tweet)
While immunoglobulin replacement for patients with CVID prevents infections, it does not correct any of the autoimmune features....keeping rheumatologists busy! Dr. Mahta Mortezavi #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
#acr19 @RheumNow
Dr West’s Pearls:
- at 40x magnification of synovial fluid, 1 WBC per hpf = 500 WBC/ uL (hence, 5 WBCs seen= 2500 WBC/uL which means the pt has an inflammatory fluid - you don’t have to wait for the lab results!) https://t.co/nChSnFq5NL
k dao KDAO2011 ( View Tweet)